Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Nuvation Bio (NUVB-WT) EBITDA (2023 - 2025)

Nuvation Bio (NUVB-WT) has disclosed EBITDA for 3 consecutive years, with -$36.6 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 27.09% to -$36.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$205.4 million through Dec 2025, up 63.81% year-over-year, with the annual reading at -$205.4 million for FY2025, 63.81% up from the prior year.
  • EBITDA for Q4 2025 was -$36.6 million at Nuvation Bio, up from -$55.6 million in the prior quarter.
  • The five-year high for EBITDA was -$10.3 million in Q4 2023, with the low at -$462.6 million in Q2 2024.
  • Average EBITDA over 3 years is -$70.9 million, with a median of -$37.6 million recorded in 2024.
  • The sharpest move saw EBITDA crashed 1993.45% in 2024, then skyrocketed 87.06% in 2025.
  • Over 3 years, EBITDA stood at -$10.3 million in 2023, then tumbled by 387.51% to -$50.3 million in 2024, then rose by 27.09% to -$36.6 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$36.6 million, -$55.6 million, and -$59.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.